{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T11:36:50Z","timestamp":1780054610709,"version":"3.54.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Key Laboratory Breeding Base of Hu'nan Oriented Fundamental and Applied Research of Innovative Pharmaceutics","award":["No.2016TP1029"],"award-info":[{"award-number":["No.2016TP1029"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mater Sci: Mater Med"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>L-glutamate is an important component of protein. It can prevent gastrointestinal damage caused by NSAIDs. We constructed two-phase enteric-coated granules of aspirin and L-glutamate compound by extrusion spheronization method and fluidized bed coating. The subliminal effective dose of L-glutamate is 100\u2009mg\/kg tested by model of gastric ulcer of rats induced by aspirin and drug administration. HPLC-UV and UV\u2013Vis methods were adopted to determine content and cumulative release of aspirin and L-glutamate as quality analysis method indexes. The prescription and process optimization were carried out with yield, sphericity and dissolution. The two-phase compound granules have good sphericity of 0.93\u2009\u00b1\u20090.05 (aspirin pellets) and 0.94\u2009\u00b1\u20090.02 (L-glutamate pellets), content of salicylic acid (0.24\u2009\u00b1\u20090.03)%, dissolution of aspirin (2.36\u2009\u00b1\u20090.11)%. Quality evaluation and preliminary stability meet the commercial requirements. The stored environment of compound preparation should be sealed in a cool and dark place.<\/jats:p>","DOI":"10.1007\/s10856-021-06594-8","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T08:16:48Z","timestamp":1630311408000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Preparation and preliminary quality evaluation of aspirin\/L-glutamate compound pellets"],"prefix":"10.1007","volume":"32","author":[{"given":"Mengchang","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenglin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binsheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songwen","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,30]]},"reference":[{"key":"6594_CR1","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3109\/00365529609031975","volume":"31","author":"JM Hansen","year":"1996","unstructured":"Hansen JM, Hallas J, Lauritsen JM, Bytzer P. Non-steroidal anti-inflammatory drugs and ulcer complications: a risk factor analysis for clinical decision-making. Scand J Gastroentero.1996;31:126\u201330. https:\/\/doi.org\/10.3109\/00365529609031975.","journal-title":"Scand J Gastroentero."},{"key":"6594_CR2","unstructured":"Zhu YZ, Yin M. Pharmacology. 7th ed. Beijing: People\u2019s Medical Publishing House; 2011."},{"key":"6594_CR3","doi-asserted-by":"publisher","first-page":"385","DOI":"10.50010\/omj.2011.101","volume":"26","author":"A Alsaeed","year":"2011","unstructured":"Alsaeed A. Gastrointestinal and cardiovascular risk of nonsteroidal anti-inflammatory drugs. Oman Med J. 2011;26:385\u201391. https:\/\/doi.org\/10.50010\/omj.2011.101.","journal-title":"Oman Med J."},{"key":"6594_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/00005344-200605001-00011","volume":"47","author":"L Laine","year":"2006","unstructured":"Laine L. GI risk and risk factors of NSAIDs. J Cardiovasc Pharm. 2006;47:60\u2013S66. https:\/\/doi.org\/10.1097\/00005344-200605001-00011.","journal-title":"J Cardiovasc Pharm"},{"key":"6594_CR5","unstructured":"Zhang L, Min LY, Gang DS. Clinical characteristics of non-steroidal anti-inflammatory drugs associated gastroduodenal ulcer bleeding. Chin J Intern Med. 2003;42:258. https:\/\/pubmed.ncbi.nlm.nih.gov\/12887811."},{"key":"6594_CR6","doi-asserted-by":"publisher","first-page":"258209","DOI":"10.1155\/2013\/258209","volume":"2013","author":"M Sinha","year":"2013","unstructured":"Sinha M, Gautam L, Shukla PK, Kaur P, Sharma S, Singh TP. Current perspectives in NSAID-induced gastropathy. Mediators Inflamm. 2013;2013:258209. https:\/\/doi.org\/10.1155\/2013\/258209.","journal-title":"Mediators Inflamm"},{"key":"6594_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2165\/11596670-000000000-00000","volume":"32","author":"A Gigante","year":"2012","unstructured":"Gigante A, Tagarro I. Non-steroidal anti-inflammatory drugs and gastroprotection with proton pump inhibitors: a focus on ketoprofen\/omeprazole. Clin Drug Invest. 2012;32:221\u201331. https:\/\/doi.org\/10.2165\/11596670-000000000-00000.","journal-title":"Clin Drug Invest"},{"key":"6594_CR8","unstructured":"Ament PW, Dicola DB, James ME. Reducing adverse effects of proton pump inhibitors. Am Fam Phys. 2012;86:66\u201370. https:\/\/www.aafp.org\/afp\/2012\/0701\/p66.html."},{"key":"6594_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000452356","volume":"95","author":"K Otani","year":"2017","unstructured":"Otani K, Tanigawa T, Watanabe T, Shimada S, Nadatani Y, Nagami Y, et al. Microbiota plays a key role in non-steroidal anti-inflammatory drug-induced small intestinal damage. Digestion. 2017;95:22\u201328. https:\/\/doi.org\/10.1159\/000452356.","journal-title":"Digestion."},{"key":"6594_CR10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.7326\/0003-4819-123-4-199508150-00001","volume":"123","author":"FE Silverstein","year":"1995","unstructured":"Silverstein FE. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:241\u20139. https:\/\/doi.org\/10.7326\/0003-4819-123-4-199508150-00001.","journal-title":"Ann Intern Med."},{"key":"6594_CR11","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1503\/cmaj.1041606","volume":"171","author":"B Sibbald","year":"2004","unstructured":"Sibbald B. Rofecoxib (Vioxx) voluntarily withdrawn from market. Can Med Assoc J. 2004;171:1027\u20138. https:\/\/doi.org\/10.1503\/cmaj.1041606.","journal-title":"Can Med Assoc J"},{"key":"6594_CR12","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2174\/156802607779941305","volume":"7","author":"SK Kulkarni","year":"2007","unstructured":"Kulkarni SK, Singh VP. Licofelone-a novel analgesic and anti-inflammatory agent. Curr Top Med Chem. 2007;7:251\u201363. https:\/\/doi.org\/10.2174\/156802607779941305.","journal-title":"Curr Top Med Chem."},{"key":"6594_CR13","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/j.1365-2982.2012.01921.x","volume":"24","author":"M Camilleri","year":"2012","unstructured":"Camilleri M, Madsen K, Spiller R, Van Meerveld BG, Verne GN. Intestinal barrier function in health and gastrointestinal disease. Neurogastroenterol Motil. 2012;24:503\u201312. https:\/\/doi.org\/10.1111\/j.1365-2982.2012.01921.x.","journal-title":"Neurogastroenterol Motil"},{"key":"6594_CR14","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.2174\/13816128113199990579","volume":"20","author":"K Amagase","year":"2014","unstructured":"Amagase K, Kimura Y, Wada A, Yukishige T, Murakami T, Nakamura E, et al. Prophylactic effect of monosodium glutamate on NSAID-induced enteropathy in rats. Curr Pharm Design. 2014;20:2783\u201390. https:\/\/doi.org\/10.2174\/13816128113199990579.","journal-title":"Curr Pharm Design"},{"key":"6594_CR15","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.3945\/jn.115.217661","volume":"145","author":"N Jiao","year":"2015","unstructured":"Jiao N, Wu ZL, Ji Y, Wang B, Dai Z, Wu G. L-Glutamate enhances barrier and antioxidative functions in intestinal porcine epithelial cells. J Nutr. 2015;145:2258\u201364. https:\/\/doi.org\/10.3945\/jn.115.217661.","journal-title":"J Nutr"},{"key":"6594_CR16","doi-asserted-by":"publisher","first-page":"e0122893","DOI":"10.1371\/journal.pone.0122893","volume":"10","author":"J Yin","year":"2015","unstructured":"Yin J, Liu MF, Ren WK, Duan JL, Yang G, Zhao YR, et al. Effects of dietary supplementation with glutamate and aspartate on diquat-induced oxidative stress in piglet. PLoS ONE. 2015;10:e0122893. https:\/\/doi.org\/10.1371\/journal.pone.0122893.","journal-title":"PLoS ONE"},{"key":"6594_CR17","doi-asserted-by":"publisher","first-page":"e112357","DOI":"10.1371\/journal.pone.0112357","volume":"9","author":"JL Duan","year":"2014","unstructured":"Duan JL, Yin J, Wu MM, Liao P, Deng D, Liu G, et al. Dietary glutamate supplementation ameliorates mycotoxin-induced abnormalities in the intestinal structure and expression of amino acid transporters in young pigs. PLoS ONE. 2014;9:e112357. https:\/\/doi.org\/10.1371\/journal.pone.0112357.","journal-title":"PLoS ONE."},{"key":"6594_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.appet.2010.05.002","volume":"55","author":"S Jinap","year":"2010","unstructured":"Jinap S, Hajeb P. Glutamate. Its applications in food and contribution to health. Appetite. 2010;55:1\u201310. https:\/\/doi.org\/10.1016\/j.appet.2010.05.002.","journal-title":"Appetite"},{"key":"6594_CR19","volume-title":"Experimental methodology of pharmacology","author":"SY Xu","year":"2002","unstructured":"Xu SY. Experimental methodology of pharmacology. 3rd ed. Beijing: People\u2019s Medical Publishing House; 2002.","edition":"3rd ed"},{"key":"6594_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10837450.2016.1265556","volume":"2016","author":"Y Xia","year":"2016","unstructured":"Xia Y, Shi CY, Fang JG, Wang WQ. Approaches to developing fast release pellets via wet extrusion-spheronization. Pharm Dev Technol. 2016;2016:1\u201310. https:\/\/doi.org\/10.1080\/10837450.2016.1265556.","journal-title":"Pharm Dev Technol"},{"key":"6594_CR21","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ejps.2003.09.009","volume":"20","author":"\u00c5 Tun\u00f3n","year":"2003","unstructured":"Tun\u00f3n \u00c5, B\u00f6rjesson E, Frenning G, Alderborn G. Drug release from reservoir pellets compacted with some excipient of different physical properties. Eur J Pharm Sci. 2003;20:469\u201379. https:\/\/doi.org\/10.1016\/j.ejps.2003.09.009.","journal-title":"Eur J Pharm Sci"},{"key":"6594_CR22","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1208\/s12249-008-9134-9","volume":"9","author":"JL Soh","year":"2008","unstructured":"Soh JL, Yang L, Liew CV, Cui FD, Heng PWS. Importance of small pores in microcrystalline cellulose for controlling water distribution during extrusion-spheronization. AAPS Pharm Sci Tech. 2008;9:972\u201381. https:\/\/doi.org\/10.1208\/s12249-008-9134-9.","journal-title":"AAPS Pharm Sci Tech"},{"key":"6594_CR23","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3109\/03639045.2013.861479","volume":"41","author":"A Goyanes","year":"2013","unstructured":"Goyanes A, Mart\u00ednez-Pacheco R. New co-processed MCC-based excipient for fast release of low solubility drugs from pellets prepared by extrusion- spheronization. Drug Dev Ind Pharm. 2013;41:362\u20138. https:\/\/doi.org\/10.3109\/03639045.2013.861479.","journal-title":"Drug Dev Ind Pharm"},{"key":"6594_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2009.12.058","volume":"389","author":"S Mascia","year":"2010","unstructured":"Mascia S, Seiler C, Fitzpatrick S, Wilson DI. Extrusion-spheronisation of microcrystalline cellulose pastes using a non- aqueous liquid binder. Int J Pharm. 2010;389:1\u20139. https:\/\/doi.org\/10.1016\/j.ijpharm.2009.12.058.","journal-title":"Int J Pharm"},{"key":"6594_CR25","unstructured":"Evonik. EUDRAGIT\u00ae medicinal acrylic resin. 2020. Access from https:\/\/healthcare.evonik.com\/in2020."},{"key":"6594_CR26","unstructured":"Liu WL, Han HL, Han JS. Preparation and in vitro evaluation of multi-unit tablets of delayed release aspirin. Shanghai Med Pharm J. 2013. http:\/\/en.cnki.com.cn\/Article_en\/CJFDTotal-SYIY201321022.htm."},{"key":"6594_CR27","unstructured":"Chen SL, Zhang J, Huang GH. Preparation and evaluation of drug release of compound aspirin and esomeprazole magnesium entericcoated pellet capsules. Chin Pharm J. 2016. http:\/\/en.cnki.com.cn\/Article_en\/CJFDTOTAL-ZGYX201612011.htm."},{"key":"6594_CR28","unstructured":"Chinese Pharmacopoeia Commission. Pharmacopoeia of the People\u2019s Republic of China. Beijing: China Medical Science Press; 2015."},{"key":"6594_CR29","doi-asserted-by":"crossref","unstructured":"Veronica N, Liew CV, Heng PWS. Insights on the role of excipients and tablet matrix porosity on aspirin stability, International Journal of Pharmaceutics. 580;2020:119218.","DOI":"10.1016\/j.ijpharm.2020.119218"}],"container-title":["Journal of Materials Science: Materials in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10856-021-06594-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10856-021-06594-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10856-021-06594-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T18:59:17Z","timestamp":1632337157000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10856-021-06594-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,30]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["6594"],"URL":"https:\/\/doi.org\/10.1007\/s10856-021-06594-8","relation":{},"ISSN":["0957-4530","1573-4838"],"issn-type":[{"value":"0957-4530","type":"print"},{"value":"1573-4838","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,30]]},"assertion":[{"value":"21 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"116"}}